Top

Published in:

01-04-2011

Human Papillomavirus Vaccination in Males: The State of the Science

Authors: Luis F. Barroso II, Timothy Wilkin

Published in: Current Infectious Disease Reports | Issue 2/2011

Abstract

Human papillomavirus (HPV) is an extremely prevalent sexually transmitted infection that is typically acquired soon after onset of sexual activity. The burden of HPV-related malignant and nonmalignant disease is high in men and women. High-risk or oncogenic types of HPV cause cervical, vaginal, and vulvar cancer in women. These types have also been shown to cause penile cancer in men and a substantial proportion of oropharyngeal and anal malignancy in men and women. Low-risk types of HPV cause anogenital warts. Prevention of penile, anal, and oropharyngeal cancers and anogenital warts represents potential benefits of the HPV vaccine in men. This review focuses on HPV disease in men, existing data on HPV vaccination in men, and various factors associated with the decision to vaccinate boys and young men, as well as the timing of vaccination.

Marur S, D’Souza G, Westra WH, Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781–9.PubMedCrossRef

Johnson LG, Madeleine MM, Newcomer LM, et al.: Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer 2004;101:281–8.PubMedCrossRef

von Krogh G, Lacey CJ, Gross G, et al.: European guideline for the management of anogenital warts. Int J STD AIDS 2001;12 Suppl 3:40–7.CrossRef

Munoz N, Bosch FX, de Sanjose S, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–27.PubMedCrossRef

Nielson CM, Flores R, Harris RB, et al.: Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 2007;16:1107–14.PubMedCrossRef

Barzon L, Militello V, Pagni S, et al.: Distribution of human papillomavirus types in the anogenital tract of females and males. J Med Virol 2010;82:1424–30.PubMedCrossRef

Giuliano AR, Lazcano-Ponce E, Villa LL, et al.: The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008;17:2036–43.PubMedCrossRef

Stebbing J, Portsmouth S, Fox P, et al.: Multiple human papillomavirus types appear to be a feature of anal not cervical intra-epithelial neoplasia. AIDS 2003;17:2401.PubMedCrossRef

Frisch M, Biggar RJ, Goedert JJ: Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500–10.PubMedCrossRef

10.

Palefsky JM, Holly EA, Ralston ML, Jay N: Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998;177:361–7.PubMedCrossRef

11.

Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 Suppl 3:S3/11–25.

12.

Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030–44.PubMedCrossRef

13.

Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–9.PubMedCrossRef

14.

Chaturvedi AK, Engels EA, Anderson WF, Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612–9.PubMedCrossRef

15.

Johnson LG, Madeleine MM, Newcomer LM, et al.: Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer 2004;101:281–8.PubMedCrossRef

16.

Hernandez BY, Barnholtz-Sloan J, German RR, et al.: Burden of invasive squamous cell carcinoma of the penis in the United States, 1998–2003. Cancer 2008;113:2883–91.PubMedCrossRef

17.

Heideman DA, Waterboer T, Pawlita M, et al.: Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 2007;25:4550–6.PubMedCrossRef

18.

Maden C, Sherman KJ, Beckmann AM, et al.: History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993;85:19–24.PubMedCrossRef

19.

Rubin MA, Kleter B, Zhou M, et al.: Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001;159:1211–8.PubMedCrossRef

20.

Tsen HF, Morgenstern H, Mack T, Peters RK: Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control 2001;12:267–77.PubMedCrossRef

21.

Chiao EY, Krown SE, Stier EA, Schrag D: A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005;40:451–5.PubMedCrossRef

22.

• Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al.: Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010, 24(4):535–43. This article supports the rising incidence of anal cancer and the idea that HAART paradoxically increases the incidence of this HIV-related condition through increased survival.PubMedCrossRef

23.

Piketty C, Selinger-Leneman H, Grabar S, et al.: Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008;22:1203–11.PubMedCrossRef

24.

Piketty C, Darragh TM, Da Costa M, et al.: High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003;138:453–9.PubMed

25.

Sunesen KG, Norgaard M, Thorlacius-Ussing O, Laurberg S: Immunosuppressive disorders and risk of anal squamous cell carcinoma: A nationwide cohort study in Denmark, 1978–2005. Int J Cancer 2009;

26.

Palefsky JM, Holly EA, Ralston ML, et al.: Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:320–6.PubMed

27.

Palefsky JM, Holly EA, Efirdc JT, et al.: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005;19:1407–14.PubMedCrossRef

28.

Marchesa P, Fazio VW, Oliart S, et al.: Perianal Bowen’s disease: a clinicopathologic study of 47 patients. Dis Colon Rectum 1997;40:1286–93.PubMedCrossRef

29.

Marfing TE, Abel ME, Gallagher DM: Perianal Bowen’s disease and associated malignancies. Results of a survey. Dis Colon Rectum 1987;30:782–5.PubMedCrossRef

30.

Berry M, Jay N, Cranston R, et al.: Progression of High-Grade Anal Intraepithelial Neoplasia to Invasive Anal Cancer among HIV+Men Who Have Sex with Men. Abstract Number 867, Conference on Retroviruses and Opportunistic Infections, Montreal Canada 2009

31.

D’Souza G, Kreimer AR, Viscidi R, et al.: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944–56.PubMedCrossRef

32.

Ragin CC, Taioli E: Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007;121:1813–20.PubMedCrossRef

33.

D’Souza G, Fakhry C, Sugar EA, et al.: Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007;121:143–50.PubMedCrossRef

34.

Clarke P, Ebel C, Catotti DN, Stewart S: The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996;7:197–200.PubMedCrossRef

35.

Smith JS, Moses S, Hudgens MG, et al.: Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis 2010;201:1677–85.PubMedCrossRef

36.

Larson DA, Derkay CS: Epidemiology of recurrent respiratory papillomatosis. APMIS 2010;118:450–4.PubMedCrossRef

37.

•• Giuliano A, Palefsky J: The efficacy of the quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men. Proceedings from the European Research Organization on Genital Infection and Neoplasia Congress 2008; Abstract TC 2–11. These phase III trials provide the most direct data for HPV vaccination of young men.

38.

•• Giuliano A, Palefsky J: Efficacy of the quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men. Proceedings from the European Research Organization on Genital Infection and Neoplasia Congress 2008; Abstract SS 19-7a. These phase III trials provide the most direct data for HPV vaccination of young men.

39.

Giuliano A, Palefsky J: Quadrivalent HPV vaccine efficacy against an HPV infection in men. 26th International Papillomavirus Conference and Clinical and Public Health Workshops [abstract P-669]. July 5, 2010, Montreal, Canada. 28

40.

Palefsky J: Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. 26th International Papillomavirus Conference & Clinical and Public Health Workshops [abstract 456]. July 5, 2010, Montreal, Canada. 29

41.

Reisinger KS, Block SL, Lazcano-Ponce E, et al.: Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26:201–9.PubMedCrossRef

42.

• Wilkin T, Lee JY, Lensing SY, et al.: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202:1246–53. This article demonstrates that HPV vaccination results in noninferior titers in HIV-infected men. This finding is particularly important given the increased disease burden of HPV in this cohort.PubMedCrossRef

43.

Brown V, White KA: The HPV vaccination strategy: could male vaccination have a significant impact? Comput Math Methods Med 2010;1.

44.

Elbasha EH, Dasbach EJ: Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;

45.

Watson JC, Hadler SC, Dykewicz CA, et al.: Measles, mumps, and rubella–vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998;47:1–57.PubMed

46.

• Kim JJ, Goldie SJ: Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884. A key article in the debate about cost effectiveness, it highlights the difficulty of computing cost effectiveness and the immense variation that can take place with variations in variables.PubMedCrossRef

47.

Annemans L, Remy V, Oyee J, Largeron N: Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009;27:231–45.PubMedCrossRef

48.

• Kim JJ: Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010;10:845–52. This article provides a clear illustration of the importance of subpopulations when assessing HPV vaccine cost effectiveness in males.PubMedCrossRef

Title: Human Papillomavirus Vaccination in Males: The State of the Science
Authors: Luis F. Barroso II
Timothy Wilkin
Publication date: 01-04-2011
Publisher: Current Science Inc.
Published in: Current Infectious Disease Reports / Issue 2/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-010-0163-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Clinical Trial Report: Duration of Metronidazole Therapy in HIV-infected Women with Trichomonas vaginalis: Is More Metronidazole Better?

Mucormycosis of the Head and Neck

Gonococcal Resistance: Are Cephalosporins Next?

Manifestations of HIV in the Head and Neck

HIV, Sexually Transmitted Infections, and Sexuality in Later Life

Clinical Trial Report: Viral Coinfections with Invasive Pneumococcal Disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials